MTVA
MetaVia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.23
−2.38%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +25.6%
- EBIT
- +25.5%
- EPS
- +79.1%
- Free cash flow
- +16.2%
- Operating cash flow
- +16.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +60.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +53.0%
- EBIT
- +52.4%
- Net income
- +53.0%
- EPS
- +81.2%
- Free cash flow
- +36.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026